Video

Dr. Philip on the Efficacy of TAS-102 in mCRC

Author(s):

Tony Philip, MD, discusses the efficacy of trifluridine/tipiracil in patients with metastatic colorectal cancer who are ineligible for intensive treatment.

Tony Philip, MD, a medical oncologist at Monter Cancer Center of the North Shore, LIJ Cancer Institute, and an assistant professor of medicine at Hofstra-North Shore LIJ School of Medicine and New York Institute of Technology College of Osteopathic Medicine, discusses the efficacy of trifluridine/tipiracil (TAS-102; Lonsurf) in patients with metastatic colorectal cancer (mCRC) who are ineligible for intensive treatment.

TAS-102 is often utilized as a last resort treatment for patients with mCRC. Although the agent is generally thought to be well tolerated, given its approval for use in the fourth- or fifth-line setting, some may not consider it to be as effective as desired, according to Philip.

TAS-102 presents an option for patients who are ineligible for intensive therapy and could be superior to previous standard treatments for this population, without any added toxicity, Philip says. This option is for patients who aren't able to tolerate multiagent chemotherapy regimens, Philip concludes.

Related Videos
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Paul Chinfai Lee, MD, discusses the role of surgeons in regard to molecular testing in non–small cell lung cancer.
Aparna Parikh, MD
Tanios Bekaii-Saab, MD, FACP
Cindy Medina Pabon, MD, assistant professor, Sylvester Cancer Center, University of Miami; assistant lead, GI Cancer Clinical Research, Gastrointestinal Medical Oncology, University of Miami Health Systems
Aparna Parikh, MD, associate professor, medicine, Harvard Medical School; assistant in medicine, Hematology, Oncology, Massachusetts General Hospital; attending oncologist, Tucker Gosnell Center for Gastrointestinal Cancers, the Henri and Belinda Termeer Center for Targeted Therapies